Giulio Ceolotto

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4639856/publications.pdf

Version: 2024-02-01

231 papers

11,368 citations

53 h-index 99 g-index

233 all docs

233 docs citations

times ranked

233

9178 citing authors

#	Article	IF	CITATIONS
1	A Prospective Study of the Prevalence of Primary Aldosteronism in 1,125 Hypertensive Patients. Journal of the American College of Cardiology, 2006, 48, 2293-2300.	2.8	1,236
2	An Expert Consensus Statement on Use of Adrenal Vein Sampling for the Subtyping of Primary Aldosteronism. Hypertension, 2014, 63, 151-160.	2.7	475
3	Renal Damage in Primary Aldosteronism. Hypertension, 2006, 48, 232-238.	2.7	424
4	The Adrenal Vein Sampling International Study (AVIS) for Identifying the Major Subtypes of Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1606-1614.	3.6	310
5	Long-Term Control of Arterial Hypertension and Regression of Left Ventricular Hypertrophy With Treatment of Primary Aldosteronism. Hypertension, 2013, 62, 62-69.	2.7	288
6	Identification of the Etiology of Primary Aldosteronism with Adrenal Vein Sampling in Patients with Equivocal Computed Tomography and Magnetic Resonance Findings: Results in 104 Consecutive Cases. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1083-1090.	3.6	271
7	Downregulation of the Longevity-Associated Protein Sirtuin 1 in Insulin Resistance and Metabolic Syndrome: Potential Biochemical Mechanisms. Diabetes, 2010, 59, 1006-1015.	0.6	268
8	Prevalence, Clinical, and Molecular Correlates of <i>KCNJ5</i> Mutations in Primary Aldosteronism. Hypertension, 2012, 59, 592-598.	2.7	246
9	Rosiglitazone Reduces Glucose-Induced Oxidative Stress Mediated by NAD(P)H Oxidase via AMPK-Dependent Mechanism. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 2627-2633.	2.4	205
10	Vascular Remodeling and Duration of Hypertension Predict Outcome of Adrenalectomy in Primary Aldosteronism Patients. Hypertension, 2008, 51, 1366-1371.	2.7	197
11	CYP1A2 genotype modifies the association between coffee intake and the risk of hypertension. Journal of Hypertension, 2009, 27, 1594-1601.	0.5	174
12	Body Mass Index Predicts Plasma Aldosterone Concentrations in Overweight-Obese Primary Hypertensive Patients. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2566-2571.	3.6	171
13	A Meta-Analysis of Somatic KCNJ5 K ⁺ Channel Mutations In 1636 Patients With an Aldosterone-Producing Adenoma. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E1089-E1095.	3.6	162
14	The T-786C endothelial nitric oxide synthase genotype is a novel risk factor for coronary artery disease in Caucasian patients of the GENICA study. Journal of the American College of Cardiology, 2003, 41, 930-937.	2.8	154
15	Interactions between endothelin-1 and the renin–angiotensin–aldosterone system. Cardiovascular Research, 1999, 43, 300-307.	3.8	152
16	Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension â—. Journal of Hypertension, 2020, 38, 1919-1928.	0.5	151
17	Adrenocorticotropic Hormone Stimulation During Adrenal Vein Sampling for Identifying Surgically Curable Subtypes of Primary Aldosteronism. Hypertension, 2009, 53, 761-766.	2.7	150
18	Adrenalectomy Lowers Incident Atrial Fibrillation in Primary Aldosteronism Patients at Long Term. Hypertension, 2018, 71, 585-591.	2.7	149

#	Article	IF	CITATIONS
19	The T-786C and Glu298Asp polymorphisms of the endothelial nitric oxide gene affect the forearm blood flow responses of Caucasian hypertensive patients. Journal of the American College of Cardiology, 2003, 41, 938-945.	2.8	139
20	Interplay Between miR-155, AT1R A1166C Polymorphism, and AT1R Expression in Young Untreated Hypertensives. American Journal of Hypertension, 2011, 24, 241-246.	2.0	135
21	Adrenal vein sampling for primary aldosteronism: the assessment of selectivity and lateralization of aldosterone excess baseline and after adrenocorticotropic hormone (ACTH) stimulation. Journal of Hypertension, 2008, 26, 989-997.	0.5	131
22	Diabetes Causes Bone Marrow Autonomic Neuropathy and Impairs Stem Cell Mobilization via Dysregulated <i>p66Shc</i> and <i>Sirt1</i> Diabetes, 2014, 63, 1353-1365.	0.6	131
23	Reduced expression of regulator of G-protein signaling 2 (RGS2) in hypertensive patients increases calcium mobilization and ERK1/2 phosphorylation induced by angiotensin II. Journal of Hypertension, 2006, 24, 1115-1124.	0.5	122
24	Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients. ELife, 2020, 9,	6.0	121
25	Widespread Increase in Myeloid Calcifying Cells Contributes to Ectopic Vascular Calcification in Type 2 Diabetes. Circulation Research, 2011, 108, 1112-1121.	4.5	109
26	Aldosterone-producing adrenocortical carcinoma: an unusual cause of Conn's syndrome with an ominous clinical course. Endocrine-Related Cancer, 2005, 12, 149-159.	3.1	107
27	Increased Expression of Regulator of G Protein Signaling-2 (RGS-2) in Bartter's/Gitelman's Syndrome. A Role in the Control of Vascular Tone and Implication for Hypertension. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 4153-4157.	3.6	106
28	Dynamic testing with high-dose adrenocorticotrophic hormone does not improve lateralization of aldosterone oversecretion in primary aldosteronism patients. Journal of Hypertension, 2006, 24, 371-379.	0.5	104
29	Positive cardiac inotropic effect of albumin infusion in rodents with cirrhosis and ascites: molecular mechanisms. Hepatology, 2013, 57, 266-276.	7.3	104
30	The antidiabetic drug metformin blunts NETosis in vitro and reduces circulating NETosis biomarkers in vivo. Acta Diabetologica, 2018, 55, 593-601.	2.5	103
31	Randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites. Hepatology, 1994, 19, 72-79.	7.3	100
32	Metformin Prevents Glucose-Induced Protein Kinase C-Â2 Activation in Human Umbilical Vein Endothelial Cells Through an Antioxidant Mechanism. Diabetes, 2005, 54, 1123-1131.	0.6	97
33	Clinical Outcomes of 1625 Patients With Primary Aldosteronism Subtyped With Adrenal Vein Sampling. Hypertension, 2019, 74, 800-808.	2.7	97
34	Primary Aldosteronism. Journal of the American College of Cardiology, 2019, 74, 2799-2811.	2.8	97
35	Galectin-3 Predicts Long-Term Cardiovascular Death in High-Risk Patients With Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 725-732.	2.4	95
36	Prospective evaluation of the saline infusion test for excluding primary aldosteronism due to aldosterone-producing adenoma. Journal of Hypertension, 2007, 25, 1433-1442.	0.5	90

3

#	Article	IF	CITATIONS
37	At the crossroads of longevity and metabolism: the metabolic syndrome and lifespan determinant pathways. Aging Cell, 2011, 10, 10-17.	6.7	88
38	11βâ€Hydroxysteroid dehydrogenase expression and activity in the human adrenal cortex. FASEB Journal, 1998, 12, 1533-1539.	0.5	79
39	Insulin Generates Free Radicals by an NAD(P)H, Phosphatidylinositol 3'-Kinase-Dependent Mechanism in Human Skin Fibroblasts Ex Vivo. Diabetes, 2004, 53, 1344-1351.	0.6	79
40	Endothelin-1 and Its mRNA in the Wall Layers of Human Arteries Ex Vivo. Circulation, 1999, 99, 1147-1155.	1.6	78
41	Impact of Accessory Hepatic Veins on Adrenal Vein Sampling for Identification of Surgically Curable Primary Aldosteronism. Hypertension, 2009, 54, 885-889.	2.7	78
42	Identification of the Etiology of Primary Aldosteronism with Adrenal Vein Sampling in Patients with Equivocal Computed Tomography and Magnetic Resonance Findings: Results in 104 Consecutive Cases. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1083-1090.	3.6	74
43	Within-Patient Reproducibility of the Aldosterone:Renin Ratio in Primary Aldosteronism. Hypertension, 2010, 55, 83-89.	2.7	70
44	The 2020 Italian Society of Arterial Hypertension (SIIA) practical guidelines for the management of primary aldosteronism. International Journal of Cardiology: Hypertension, 2020, 5, 100029.	2.2	69
45	Red Blood Cell Na+/H+ and Li+/Na+ Exchange in Patients With Essential Hypertension. American Journal of Hypertension, 1989, 2, 903-908.	2.0	67
46	Subtyping of Primary Aldosteronism in the AVIS-2 Study: Assessment of Selectivity and Lateralization. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2042-2052.	3.6	65
47	Quantitative Value of Aldosteroneâ€Renin Ratio for Detection of Aldosteroneâ€Producing Adenoma: The Aldosteroneâ€Renin Ratio for Primary Aldosteronism (AQUARR) Study. Journal of the American Heart Association, 2017, 6, .	3.7	64
48	miR-30c-5p regulates macrophage-mediated inflammation and pro-atherosclerosis pathways. Cardiovascular Research, 2017, 113, 1627-1638.	3.8	62
49	Hyperparathyroidism Can Be Useful in the Identification of Primary Aldosteronism Due To Aldosterone-Producing Adenoma. Hypertension, 2012, 60, 431-436.	2.7	61
50	Prospective validation of an automated chemiluminescence-based assay of renin and aldosterone for the work-up of arterial hypertension. Clinical Chemistry and Laboratory Medicine, 2016, 54, 1441-1450.	2.3	61
51	The aldosterone–renin ratio based on the plasma renin activity and the direct renin assay for diagnosing aldosterone-producing adenoma. Journal of Hypertension, 2010, 28, 1892-1899.	0.5	60
52	Arterial Hypertension, Atrial Fibrillation, and Hyperaldosteronism. Hypertension, 2017, 69, 545-550.	2.7	59
53	Antibodies to Oxidized Low-Density Lipoproteins and Angiographically Assessed Coronary Artery Disease in White Patients. Circulation, 2003, 108, 2467-2472.	1.6	56
54	Circulating levels and characterization of microparticles in patients with different degrees of glucose tolerance. Cardiovascular Diabetology, 2017, 16, 118.	6.8	55

#	Article	IF	CITATIONS
55	Lipoprotein-associated phospholipase A2 prognostic role in atherosclerotic complications. World Journal of Cardiology, 2015, 7, 609.	1.5	55
56	The Tâ^'786C Endothelial Nitric Oxide Synthase Genotype Predicts Cardiovascular Mortality in High-Risk Patients. Journal of the American College of Cardiology, 2006, 48, 1166-1174.	2.8	52
57	The sympathetic nervous system and catecholamines metabolism in obstructive sleep apnoea. Journal of Thoracic Disease, 2016, 8, 243-54.	1.4	52
58	Clinical Use of Laboratory Tests for the Identification of Secondary Forms of Arterial Hypertension. Critical Reviews in Clinical Laboratory Sciences, 2007, 44, 1-85.	6.1	49
59	GPER-1 and Estrogen Receptor- \hat{l}^2 Ligands Modulate Aldosterone Synthesis. Endocrinology, 2014, 155, 4296-4304.	2.8	49
60	NAD+-dependent SIRT1 deactivation has a key role on ischemia–reperfusion-induced apoptosis. Vascular Pharmacology, 2015, 70, 35-44.	2.1	48
61	Atrial fibrillation as presenting sign of primary aldosteronism: results of the Prospective Appraisal on the Prevalence of Primary Aldosteronism in Hypertensive (PAPPHY) Study. Journal of Hypertension, 2020, 38, 332-339.	0.5	48
62	Abnormalities of Gq-mediated cell signaling in Bartter and Gitelman syndromes 1*1See Editorial by Warnock, p. 1197. Kidney International, 2001, 60, 882-889.	5.2	46
63	Adrenal Histopathology in Primary Aldosteronism. Hypertension, 2015, 66, 724-730.	2.7	44
64	Randomised sham-controlled trial of transcutaneous electrical stimulation in obstructive sleep apnoea. Thorax, 2016, 71, 923-931.	5.6	44
65	Silencing regulator of G protein signaling-2 (RGS-2) increases angiotensin II signaling: insights into hypertension from findings in Bartter's/Gitelman's syndromes. Journal of Hypertension, 2008, 26, 938-945.	0.5	42
66	KCNJ5 gene somatic mutations affect cardiac remodelling but do not preclude cure of high blood pressure and regression of left ventricular hypertrophy in primary aldosteronism. Journal of Hypertension, 2014, 32, 1514-1522.	0.5	42
67	New concepts in adrenal vein sampling for aldosterone in the diagnosis of primary aldosteronism. Current Hypertension Reports, 2007, 9, 90-97.	3.5	41
68	Cardiac Remodeling in Patients With Primary and Secondary Aldosteronism. Circulation: Cardiovascular Imaging, 2016, 9, .	2.6	41
69	The Biology of Normal Zona Glomerulosa And Aldosterone-Producing Adenoma: Pathological Implications. Endocrine Reviews, 2018, 39, 1029-1056.	20.1	40
70	Vitamin C prevents zidovudine-induced NAD(P)H oxidase activation and hypertension in the rat. Cardiovascular Research, 2007, 73, 432-438.	3.8	39
71	Androstenedione and 17-î±-Hydroxyprogesterone Are Better Indicators of Adrenal Vein Sampling Selectivity Than Cortisol. Hypertension, 2017, 70, 342-346.	2.7	38
72	Practice Recommendations for Diagnosis and Treatment of the Most Common Forms of Secondary Hypertension. High Blood Pressure and Cardiovascular Prevention, 2020, 27, 547-560.	2.2	38

#	Article	IF	Citations
73	Primary aldosteronism: A needle in a haystack or a yellow cab on fifth avenue?. Current Hypertension Reports, 2004, 6, 1-4.	3.5	37
74	Endothelin-1-induced arachidonic acid release by cytosolic phospholipase A2 activation in rat vascular smooth muscle via extracellular signal-regulated kinases pathway. Biochemical Pharmacology, 2002, 64, 425-431.	4.4	36
75	Atrial fibrillation and arterial hypertension: A common duet with dangerous consequences where the renin angiotensin-aldosterone system plays an important role. International Journal of Cardiology, 2016, 206, 71-76.	1.7	36
76	Surgically correctable hypertension caused by primary aldosteronism. Best Practice and Research in Clinical Endocrinology and Metabolism, 2006, 20, 385-400.	4.7	35
77	Angiotensin II Type 1 Receptor Gene Polymorphism Predicts Development of Hypertension and Metabolic Syndrome. American Journal of Hypertension, 2009, 22, 208-214.	2.0	35
78	Sirtuin 1 stabilization by HuR represses TNF- \hat{l}_{\pm} - and glucose-induced E-selectin release and endothelial cell adhesiveness (i) in Avitro (i): relevance to human metabolic syndrome. Clinical Science, 2014, 127, 449-461.	4.3	35
79	Update in adrenal venous sampling for primary aldosteronism. Current Opinion in Endocrinology, Diabetes and Obesity, 2018, 25, 160-171.	2.3	35
80	Adiponectin receptor expression in the human adrenal cortex and aldosterone-producing adenomas. International Journal of Molecular Medicine, 2006, 17, 975-80.	4.0	35
81	Effects of angiotensin II and insulin on ERK1/2 activation in fibroblasts from hypertensive patients*1. American Journal of Hypertension, 2004, 17, 604-610.	2.0	34
82	Treatment of atherosclerotic renovascular hypertension: review of observational studies and a meta-analysis of randomized clinical trials. Nephrology Dialysis Transplantation, 2015, 30, 541-553.	0.7	34
83	Endothelinâ€1 Drives Epithelialâ€Mesenchymal Transition in Hypertensive Nephroangiosclerosis. Journal of the American Heart Association, 2016, 5, .	3.7	34
84	Endothelin-1[1-31], acting as an ETA-receptor selective agonist, stimulates proliferation of cultured rat zona glomerulosa cells. FEBS Letters, 2000, 487, 194-198.	2.8	32
85	Aortic smooth muscle cell phenotypic modulation and fibrillar collagen deposition in angiotensin II-dependent hypertension. Cardiovascular Research, 2002, 55, 178-189.	3.8	32
86	An abnormal gene expression of the \hat{l}^2 -adrenergic system contributes to the pathogenesis of cardiomyopathy in cirrhotic rats. Hepatology, 2008, 48, 1913-1923.	7. 3	32
87	Endothelin receptor blockade lowers plasma aldosterone levels via different mechanisms in primary aldosteronism and high-to-normal renin hypertension. Cardiovascular Research, 2003, 57, 277-283.	3.8	31
88	Diagnosis and Treatment of Primary Aldosteronism. Endocrinology and Metabolism Clinics of North America, 2011, 40, 313-332.	3.2	30
89	Adrenal Venous Sampling Versus Computed Tomographic Scan to Determine Treatment in Primary Aldosteronism (The SPARTACUS Trial). Hypertension, 2017, 69, 396-397.	2.7	30
90	Effects of Mineralocorticoid and AT1 Receptor Antagonism on The Aldosterone-Renin Ratio In Primary Aldosteronism—the EMIRA Study. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2060-2067.	3.6	30

#	Article	IF	Citations
91	Molecular biology based assessment of green tea effects on oxidative stress and cardiac remodelling in dialysis patients. Clinical Nutrition, 2014, 33, 437-442.	5.0	29
92	MAPKinase and regulation of the sodium–proton exchanger in human red blood cell. Biochimica Et Biophysica Acta - Biomembranes, 1999, 1421, 140-148.	2.6	28
93	The molecular basis of primary aldosteronism: from chimeric gene to channelopathy. Current Opinion in Pharmacology, 2015, 21, 35-42.	3.5	28
94	Effect of Continuous Positive Airway Pressure on Blood Pressure Variability in Patients With Obstructive Sleep Apnea. Journal of Clinical Hypertension, 2016, 18, 1180-1184.	2.0	28
95	Macrolides Blunt Aldosterone Biosynthesis. Hypertension, 2017, 70, 1238-1242.	2.7	28
96	The effect of positive and negative message framing on short term continuous positive airway pressure compliance in patients with obstructive sleep apnea. Journal of Thoracic Disease, 2018, 10, \$160-\$169.	1.4	28
97	Estrogen Signaling in the Adrenal Cortex. Hypertension, 2016, 68, 840-848.	2.7	27
98	Genetic screening in arterial hypertension. Nature Reviews Endocrinology, 2017, 13, 289-298.	9.6	27
99	Saga of Familial Hyperaldosteronism. Hypertension, 2018, 71, 1010-1014.	2.7	27
100	High sodium intake, glomerular hyperfiltration, and protein catabolism in patients with essential hypertension. Cardiovascular Research, 2021, 117, 1372-1381.	3.8	27
101	Renovascular Hypertension with Low-to-Normal Plasma Renin: Clinical and Angiographic Features. Clinical Science, 1997, 93, 435-443.	4.3	26
102	Macrolides for KCNJ5–mutated aldosterone-producing adenoma (MAPA): design of a study for personalized diagnosis of primary aldosteronism. Blood Pressure, 2018, 27, 200-205.	1.5	25
103	Transcription Factors Regulation in Human Peripheral White Blood Cells during Hypobaric Hypoxia Exposure: an in-vivo experimental study. Scientific Reports, 2019, 9, 9901.	3.3	25
104	The Helicobacter cinaedi antigen CAIP participates in atherosclerotic inflammation by promoting the differentiation of macrophages in foam cells. Scientific Reports, 2017, 7, 40515.	3.3	24
105	Adrenal Vein Sampling Is the Preferred Method to Select Patients With Primary Aldosteronism for Adrenalectomy. Hypertension, 2018, 71, 5-9.	2.7	24
106	Effects of amiloride on renal lithium handling in nonazotemic ascitic cirrhotic patients with avid sodium retention. Hepatology, 1992, 15, 651-654.	7.3	23
107	Ouabain-inhibiting activity of aldosterone antagonists. Steroids, 1995, 60, 110-113.	1.8	23
108	Insulin generates free radicals in human fibroblasts ex vivo by a protein kinase C-dependent mechanism, which is inhibited by pravastatin. Free Radical Biology and Medicine, 2006, 41, 473-483.	2.9	23

#	Article	IF	Citations
109	Electrical stimulation for the treatment of obstructive sleep apnoea: a review of the evidence. Expert Review of Respiratory Medicine, 2017 , 11 , 711 - 720 .	2.5	23
110	The Key Role of Epithelial to Mesenchymal Transition (EMT) in Hypertensive Kidney Disease. International Journal of Molecular Sciences, 2019, 20, 3567.	4.1	23
111	Aldosterone synthase inhibitors for cardiovascular diseases: A comprehensive review of preclinical, clinical and in silico data. Pharmacological Research, 2021, 163, 105332.	7.1	23
112	Adrenomedullin stimulates DNA synthesis of rat adrenal zona glomerulosa cells through activation of the mitogen-activated protein kinase-dependent cascade. Journal of Hypertension, 2001, 19, 599-602.	0.5	22
113	Hyperhomocysteinemia predicts total and cardiovascular mortality in high-risk women. Journal of Hypertension, 2006, 24, 851-859.	0.5	22
114	Dual ACE and NEP Inhibitors: A Review of the Pharmacological Properties of MDL 100,240. Cardiovascular Drug Reviews, 2003, 21, 51-66.	4.1	22
115	Arterial Hypertension, Aldosterone, and Atrial Fibrillation. Current Hypertension Reports, 2019, 21, 94.	3.5	22
116	Callipeltin A: sodium ionophore effect and tension development in vascular smooth muscle. Biochemical Pharmacology, 2004, 68, 1331-1338.	4.4	21
117	Aldosterone breakthrough during ras blockade: A role for endothelins and their antagonists?. Current Hypertension Reports, 2006, 8, 262-268.	3.5	21
118	Genetic Variation in the Endothelin System: Do Polymorphisms Affect the Therapeutic Strategies?. Annals of the New York Academy of Sciences, 2006, 1069, 34-50.	3.8	20
119	The Intra-Procedural Cortisol Assay During Adrenal Vein Sampling: Rationale and Design of a Randomized Study (I-Padua). High Blood Pressure and Cardiovascular Prevention, 2017, 24, 167-170.	2.2	19
120	Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part I. Journal of Hypertension, 2018, 36, 451-461.	0.5	19
121	Adrenal Venous Sampling. Endocrinology and Metabolism Clinics of North America, 2019, 48, 843-858.	3.2	19
122	Drug-resistant hypertension in primary aldosteronism patients undergoing adrenal vein sampling: the AVIS-2-RH study. European Journal of Preventive Cardiology, 2022, 29, e85-e93.	1.8	19
123	Effects of insomnia and restless legs syndrome on sleep arterial blood pressure: A systematic review and meta-analysis. Sleep Medicine Reviews, 2021, 59, 101497.	8.5	19
124	Effect of unilateral adrenalectomy on the quality of life of patients with lateralized primary aldosteronism. BMC Surgery, 2019, 18, 105.	1.3	18
125	Identification of Surgically Curable Primary Aldosteronism by Imaging in a Large, Multiethnic International Study. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4340-e4349.	3.6	18
126	Comparative effects of the dual ACE-NEP inhibitor MDL-100,240 and ramipril on hypertension and cardiovascular disease in endogenous angiotensin II-dependent hypertension. American Journal of Hypertension, 2002, 15, 181-188.	2.0	17

#	Article	IF	CITATIONS
127	Clinical Management of Primary Aldosteronism. High Blood Pressure and Cardiovascular Prevention, 2014, 21, 71-75.	2.2	17
128	Normoaldosteronemic aldosterone-producing adenoma. Journal of Hypertension, 2015, 33, 2546-2549.	0.5	17
129	Metoclopramide unmasks potentially misleading contralateral suppression in patients undergoing adrenal vein sampling for primary aldosteronism. Journal of Hypertension, 2016, 34, 2258-2265.	0.5	17
130	The angiotensin type 2 receptor in the human adrenocortical zona glomerulosa and in aldosterone-producing adenoma: low expression and no functional role. Clinical Science, 2018, 132, 627-640.	4.3	17
131	Role of estrogen receptors in modulating aldosterone biosynthesis and blood pressure. Steroids, 2019, 152, 108486.	1.8	17
132	Hyperglycemia Acutely Increases Monocyte Extracellular Signal-Regulated Kinase Activity in Vivo in Humans. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1301-1305.	3.6	16
133	Abnormal regulation of G protein $\hat{l}\pm i2$ subunit in skin fibroblasts from insulin-resistant hypertensive individuals. Journal of Hypertension, 2004, 22, 783-792.	0.5	16
134	RGS2 C1114G polymorphism and body weight gain in hypertensive patients. Metabolism: Clinical and Experimental, 2008, 57, 421-427.	3.4	16
135	RGS2 expression and aldosterone: renin ratio modulate response to drug therapy in hypertensive patients. Journal of Hypertension, 2010, 28, 1104-1108.	0.5	16
136	A useful tool to improve the case detection rate of primary aldosteronism. Journal of Hypertension, 2016, 34, 1019-1021.	0.5	16
137	Approach to the surgical management of primary aldosteronism. Gland Surgery, 2015, 4, 69-81.	1.1	16
138	The Time has Come for Systematic Screening for Primary Aldosteronism inÂAllÂHypertensives â^—. Journal of the American College of Cardiology, 2017, 69, 1821-1823.	2.8	15
139	Aldosterone Stimulates Its Biosynthesis Via a Novel GPER-Mediated Mechanism. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 6316-6324.	3.6	15
140	<i>IN VITRO</i> AUTORADIOGRAPHIC DEMONSTRATION OF ENDOTHELIN-1 BINDING SITES IN THE HUMAN ADRENAL /b>CORTEX , 15, 95-99.	0.9	15
141	10 good reasons why adrenal vein sampling is the preferred method for referring primary aldosteronism patients for adrenalectomy. Journal of Hypertension, 2019, 37, 603-611.	0.5	14
142	Bartter/Gitelman syndromes as a model to study systemic oxidative stress in humans. Free Radical Biology and Medicine, 2015, 88, 51-58.	2.9	13
143	Primary aldosteronism patients show skin alterations and abnormal activation of glucocorticoid receptor in keratinocytes. Scientific Reports, 2017, 7, 15806.	3.3	13
144	Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part II. Journal of Hypertension, 2018, 36, 462-471.	0.5	13

#	Article	IF	Citations
145	AT1AA (Angiotensin II Type-1 Receptor Autoantibodies). Hypertension, 2019, 74, 793-799.	2.7	13
146	Feasibility of Imaging-Guided Adrenalectomy in Young Patients With Primary Aldosteronism. Hypertension, 2022, 79, 187-195.	2.7	13
147	SERPINB3 is associated with longer survival in transgenic mice. Scientific Reports, 2013, 3, 3056.	3.3	12
148	G-Protein \hat{l}^2 3-Subunit Gene C825T Polymorphism and Cardiovascular Risk: An Updated Review. High Blood Pressure and Cardiovascular Prevention, 2015, 22, 225-232.	2.2	12
149	Review of Markers of Zona Glomerulosa and Aldosterone-Producing Adenoma Cells. Hypertension, 2017, 70, 867-874.	2.7	12
150	Clinical efficacy and safety of angiogenesis inhibitors: sex differences and current challenges. Cardiovascular Research, 2022, 118, 988-1003.	3.8	12
151	Comparison of Cortisol, Androstenedione and Metanephrines to Assess Selectivity and Lateralization of Adrenal Vein Sampling in Primary Aldosteronism. Journal of Clinical Medicine, 2021, 10, 4755.	2.4	12
152	Secondary Hypertension: The Ways of Management. Current Vascular Pharmacology, 2010, 8, 753-768.	1.7	11
153	Angiotensin II Promotes SARS-CoV-2 Infection via Upregulation of ACE2 in Human Bronchial Cells. International Journal of Molecular Sciences, 2022, 23, 5125.	4.1	11
154	Synthesis and Biological Characterization of a New Norbormide Derived Bodipy FL-Conjugated Fluorescent Probe for Cell Imaging. Frontiers in Pharmacology, 2018, 9, 1055.	3.5	10
155	Tissue kallikrein gene polymorphisms induce no change in endothelium-dependent or independent vasodilation in hypertensive and normotensive subjects. Journal of Hypertension, 2006, 24, 1955-1963.	0.5	9
156	Expression and functional role of the prorenin receptor in the human adrenocortical zona glomerulosa and in primary aldosteronism. Journal of Hypertension, 2015, 33, 1014-1022.	0.5	9
157	Excessive daytime sleepiness does not correlate with sympathetic nervous system activation and arterial stiffening in patients with mild-to-moderate obstructive sleep apnoea: A proof-of-principle study. International Journal of Cardiology, 2017, 236, 458-461.	1.7	9
158	The acute effect of continuous positive airway pressure titration on blood pressure in awake overweight/obese patients with obstructive sleep apnoea. Blood Pressure, 2018, 27, 206-214.	1.5	9
159	Simultaneous bilateral adrenal vein sampling for primary aldosteronism: useful tips to make it simple and safe. European Radiology, 2019, 29, 6330-6335.	4.5	9
160	The cardiovascular consequences of hyperaldosteronism. Annales D'Endocrinologie, 2021, 82, 174-178.	1.4	9
161	Aldosterone and cortisol synthesis regulation by angiotensin-(1-7) and angiotensin-converting enzyme 2 in the human adrenal cortex. Journal of Hypertension, 2021, 39, 1577-1585.	0.5	9
162	Nocturnal pulse rate and symptomatic response in patients with obstructive sleep apnoea treated with continuous positive airway pressure for one year. Journal of Thoracic Disease, 2014, 6, 598-605.	1.4	9

#	Article	IF	CITATIONS
163	Modulatory effect of insulin on release of calcium from human fibroblasts by angiotensin II. Journal of Hypertension, 1998, 16, 487-493.	0.5	8
164	Changes in aldosterone and obesity-related cardiometabolic risk factors with a 1-year weight loss intervention in normotensive overweight and obese young adults. Hypertension Research, 2013, 36, 856-858.	2.7	8
165	Adrenal venous sampling in dye-allergic primary aldosteronism patients. Journal of Hypertension, 2018, 36, 1942-1944.	0.5	8
166	A systematic review of pathophysiology and management of familial hyperaldosteronism type 1 in pregnancy. Endocrine, 2021, 74, 5-10.	2.3	8
167	Ambulatory Systolic Blood Pressure is Related to the Deletion Allele of the Angiotensin I Converting Enzyme Gene in Young Normotensives with Parental History of Hypertension. Clinical and Experimental Hypertension, 1998, 20, 283-294.	1.3	7
168	Impaired hemodynamic response to meal intake in insulin-resistant subjects: an impedance cardiography approach. American Journal of Clinical Nutrition, 2011, 93, 926-933.	4.7	7
169	Ultrafiltration for the treatment of congestion: a window into the lung for a better caress to the heart. Nephrology Dialysis Transplantation, 2014, 29, 1335-1341.	0.7	7
170	Mineralocorticoid Receptor Antagonists Therapy in Resistant Hypertension: Time to Implement Guidelines!. Frontiers in Cardiovascular Medicine, 2015, 2, 3.	2.4	7
171	Adrenal vein sampling versus CT scanning in primary aldosteronism. Lancet Diabetes and Endocrinology,the, 2016, 4, 886.	11.4	7
172	Low P66shc with High SerpinB3 Levels Favors Necroptosis and Better Survival in Hepatocellular Carcinoma. Biology, 2021, 10, 363.	2.8	7
173	Resolution of drug-resistant hypertension by adrenal vein sampling-guided adrenalectomy: a proof-of-concept study. Clinical Science, 2020, 134, 1265-1278.	4.3	7
174	Identification of glucocorticoid-related molecular signature by whole blood methylome analysis. European Journal of Endocrinology, 2022, 186, 297-308.	3.7	7
175	Mutations of the Twik-Related Acid-Sensitive K+ Channel 2 Promoter in Human Primary Aldosteronism. Endocrinology, 2018, 159, 1352-1359.	2.8	6
176	Excess Arterial Damage in Hyperaldosteronism. Hypertension, 2019, 74, 502-504.	2.7	6
177	Effects of mineralocorticoid and AT-1 receptor antagonism on the aldosterone–renin ratio (ARR) in primary aldosteronism patients (EMIRA Study): rationale and design. Journal of Human Hypertension, 2019, 33, 167-171.	2.2	6
178	Familial hyperaldosteronism type 1 and pregnancy: successful treatment with low dose dexamethasone. Blood Pressure, 2021, 30, 133-137.	1.5	6
179	Functional imaging by 11C-metomidate PET: a really useless technique for primary aldosteronism subtyping?. European Journal of Endocrinology, 2021, 184, L9-L10.	3.7	6
180	Peptidergic G Protein–Coupled Receptor Regulation of Adrenal Function: Bench to Bedside and Back. Endocrine Reviews, 2022, 43, 1038-1050.	20.1	6

#	Article	IF	CITATIONS
181	Altered regulation of endothelin A receptor subtype in the cerebral arterioles in response to a Japanese-style diet, in stroke-prone hypertensive rats. Journal of Hypertension, 2003, 21, 105-113.	0.5	5
182	Homocysteine, left ventricular dysfunction and coronary artery disease: is there a link?. Clinical Chemistry and Laboratory Medicine, 2007, 45, 1645-51.	2.3	5
183	Human IgGs induce synthesis and secretion of IgGs and neonatal Fc receptor in human umbilical vein endothelial cells. Immunobiology, 2016, 221, 1329-1342.	1.9	5
184	Unifocal and Multifocal Fibromuscular Dysplasia. Hypertension, 2019, 73, 7-12.	2.7	5
185	Randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites. Hepatology, 1994, 19, 72-79.	7.3	5
186	Hyperglycemia Acutely Increases Monocyte Extracellular Signal-Regulated Kinase Activity in Vivo in Humans. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1301-1305.	3.6	5
187	Role of the Endogenous Adrenomedullin System in Regulating the Secretion and Growth of Rat Adrenal Cortex. Hypertension Research, 2003, 26, S85-S92.	2.7	5
188	Red Blood Cell Li+/Na+Exchange in Patients with Diabetic Nephropathy and Essential Hypertension: Therapeutic Implications. Renal Failure, 1993, 15, 331-338.	2.1	4
189	Different Effect of Ouabain on Endothelin-1–Induced Extracellular Signal-Regulated Kinase Stimulation in Rat Heart and Tail Artery. Journal of Cardiovascular Pharmacology, 2003, 41, 553-561.	1.9	4
190	Urotensin II Exerts Pressor Effects By Stimulating Renin And Aldosterone Synthase Gene Expression. Scientific Reports, 2017, 7, 13876.	3.3	4
191	Does angiotensin <scp>II</scp> regulate parathyroid hormone secretion or not?. Clinical Endocrinology, 2018, 89, 568-569.	2.4	4
192	Gitelmanâ \in TM s Syndrome: characterization of a novel c.1181G>A point mutation and functional classification of the known mutations. Hypertension Research, 2018, 41, 578-588.	2.7	4
193	Primary aldosteronism in elderly, old, and very old patients. Journal of Human Hypertension, 2020, 34, 807-813.	2.2	4
194	Disease monitoring of Primary Aldosteronism. Best Practice and Research in Clinical Endocrinology and Metabolism, 2020, 34, 101417.	4.7	4
195	Vitamin D supplementation: a novel therapy for aldosteronism?. Nature Reviews Endocrinology, 2020, 16, 303-304.	9.6	4
196	Management of hypertensive emergencies: a practical approach. Blood Pressure, 2021, 30, 208-219.	1.5	4
197	Dopaminergic Regulation of Aldosterone Secretion in Primary Aldosteronism: A Clinical Study Hypertension Research, 1994, 17, 105-115.	2.7	4
198	Modern Management of Hypertensive Emergencies. High Blood Pressure and Cardiovascular Prevention, 2022, 29, 33-40.	2.2	4

#	Article	IF	CITATIONS
199	Preanalytical Considerations and Outpatient Versus Inpatient Tests of Plasma Metanephrines to Diagnose Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3689-e3698.	3.6	4
200	Endothelin-1 in angiotensin II-dependent hypertension Answer to the Letter to the Editor. Cardiovascular Research, 1999, 44, 450-451.	3.8	3
201	An App for the Diagnosis of Primary Aldosteronism. American Journal of Hypertension, 2016, 29, 660-661.	2.0	3
202	Assessment of the Quantitative Value Usefulness of the Aldosterone-Renin Ratio (ARR) for Primary Aldosteronism (AQUARR) Study. High Blood Pressure and Cardiovascular Prevention, 2016, 23, 19-23.	2,2	3
203	Case of Asymptomatic Carotid Artery Stenosis in a Hypertensive Patient. Hypertension, 2017, 69, 985-991.	2.7	3
204	Aortic stenting in the growing sheep causes aortic endothelial dysfunction but not hypertension: Clinical implications for coarctation repair. Congenital Heart Disease, 2017, 12, 74-83.	0.2	3
205	Cure With Cryoablation of Arterial Hypertension Due to a Renin-Producing Tumor. American Journal of Hypertension, 2018, 31, 537-540.	2.0	3
206	Drug-Resistant Hypertension. Hypertension, 2019, 73, 920-925.	2.7	3
207	Heterogenous Responses to Cosyntropin in Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e882-e884.	3.6	3
208	Gαi2 expression, hypertension and insulin resistance. Journal of Hypertension, 2006, 24, 785.	0.5	2
209	Mineralocorticoid receptor antagonism as an add-on treatment for resistant hypertension. Hypertension Research, 2014, 37, 1029-1031.	2.7	2
210	The Challenges of Arterial Hypertension. Frontiers in Cardiovascular Medicine, 2015, 2, 2.	2.4	2
211	The Key Role of CT for Success of Adrenal Venous Sampling Illustrated by a Unique Clinical Case. High Blood Pressure and Cardiovascular Prevention, 2019, 26, 139-141.	2.2	2
212	Letter to the Editor from Rui Zhu et al: "Performance of the Aldosterone-to-Renin Ratio as a Screening Test for Primary Aldosteronism: A Systematic Review and Meta-Analysis― Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4292-e4293.	3.6	2
213	Letter to editor on "Thirtyâ€sixâ€month results of laparoscopicâ€based renal denervation plus unilateral laparoscopic adrenalectomy for the treatment of patients with resistant hypertension caused by unilateral aldosteroneâ€producing Adenoma― Journal of Clinical Hypertension, 2022, 24, 204-205.	2.0	2
214	Disease of Adrenal Glands. International Journal of Endocrinology, 2015, 2015, 1-2.	1.5	1
215	The Aldosterone Renin Ratio (ARR) APP as Tool to Enhance the Detection Rate of Primary Aldosteronism. High Blood Pressure and Cardiovascular Prevention, 2016, 23, 147-149.	2.2	1
216	Case of Primary Aldosteronism With Discordant Hormonal and Computed Tomographic Findings. Hypertension, 2017, 69, 529-535.	2.7	1

#	Article	IF	CITATIONS
217	Excessive daytime sleepiness, sympathetic nervous system activation and arterial stiffening in patients with mild-to-moderate obstructive sleep apnoea. Reply. International Journal of Cardiology, 2017, 249, 415-416.	1.7	1
218	Mineralocorticoid receptor antagonists. Journal of Hypertension, 2018, 36, 1015-1018.	0.5	1
219	Letter to the editor on "Ablation versus laparoscopic adrenalectomy for the treatment of aldosterone-producing adenoma: a meta-analysisâ€. Abdominal Radiology, 2021, 46, 3523-3524.	2.1	1
220	Letter to the Editor From Paolo Rossi and Rossitto: "Mineralocorticoid Receptor Antagonist Effect on Aldosterone to Renin Ratio in Patients With Primary Aldosteronism― Journal of Clinical Endocrinology and Metabolism, 2022, 107, e892-e893.	3 . 6	1
221	Captopril-stimulated renin in the diagnosis of restenosis after percutaneous transluminal renal angioplasty International Heart Journal, 1986, 27, 299-305.	0.6	1
222	<i>IN VITRO</i> AUTORADIOGRAPHIC DEMONSTRATION OF ENDOTHELIN RECEPTORS A AND B IN THE HUMAN PARATHYROID GLAND . Biomedical Research, 1996, 17, 355-358.	0.9	1
223	Adrenal Venous Sampling for Primary Aldosteronism. , 2019, , 613-622.		1
224	Effects of angiotensin II and insulin on ERK $1/2$ in human skin fibroblasts. American Journal of Hypertension, 2001, 14, A170.	2.0	0
225	Gastone Giovanni Nussdorfer. Hypertension, 2008, 51, 586-587.	2.7	0
226	Response to Is the Aldosterone: Renin Ratio Truly Reproducible?. Hypertension, 2010, 55, .	2.7	0
227	Reply. Journal of Hypertension, 2016, 34, 1882-1883.	0.5	0
228	A sleep apnoea questionnaire predicts organ damage in hypertensive patients. Blood Pressure, 2019, 28, 173-183.	1.5	0
229	Urinary sodium potassium ratio is associated with clinical success after adrenalectomy in patients with unilateral primary aldosteronism. Therapeutic Advances in Chronic Disease, 2021, 12, 204062232110226.	2.5	0
230	Letter to the Editor from Zhu and Rossi: "Development and Validation of Criteria for Sparing Confirmatory Tests in Diagnosing Primary Aldosteronism― Journal of Clinical Endocrinology and Metabolism, 2021, 106, e1496-e1497.	3.6	0
231	Response from the authors to the letter "Pulse rate trends in obstructive sleep apnoea: a reliable tool to predict long term response to CPAP?". Journal of Thoracic Disease, 2014, 6, E200-1.	1.4	0